IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.
about
STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumorsMonoclonal antibodies.Engineered SIRPĪ± variants as immunotherapeutic adjuvants to anticancer antibodies.Rituximab: mechanism of actionThe emerging role of ofatumumab in the treatment of chronic lymphocytic leukemiaClonogenic multiple myeloma progenitors, stem cell properties, and drug resistanceB cells as a therapeutic target in autoimmune diseaseCharacterization of lymphocyte populations in nonspecific interstitial pneumoniaRecent advances in the field of anti-cancer immunotherapyNovel immunotherapies in lymphoid malignanciesTargeted Therapies in Adult B-Cell MalignanciesImmune Reactivation by Cell-Free Fetal DNA in Healthy Pregnancies Re-Purposed to Target Tumors: Novel Checkpoint Inhibition in Cancer TherapeuticsHepatitis B virus reactivation with a rituximab-containing regimenHepatitis B virus reactivation with rituximab-containing regimenNovel immunotherapies for hematologic malignanciesBiologics in dermatology: an integrated reviewEvaluation of current cancer immunotherapy: hemato-oncologyImmunotherapy strategies for multiple myeloma: the present and the futureGlypican-3 Targeting Immunotoxins for the Treatment of Liver CancerAre BiTEs the "missing link" in cancer therapy?Receptor occupancy assessment by flow cytometry as a pharmacodynamic biomarker in biopharmaceutical developmentA pretargeting system for tumor PET imaging and radioimmunotherapyHarnessing the Microbiome to Enhance Cancer ImmunotherapyFc Gamma Receptor 3A and 2A Polymorphisms Do Not Predict Response to Rituximab in Follicular LymphomaComparability of a three-dimensional structure in biopharmaceuticals using spectroscopic methods.Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised hostPlacebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphomaExhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patientsFractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia.Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab.Characterization of CD4 T Cell Epitopes of Infliximab and Rituximab Identified from Healthy Donors.The potential effect of statins on rituximab immunotherapy.Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpuraThe potential utility of B cell-directed biologic therapy in autoimmune diseases.Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab.Anti-CD20 Antibody is Effective in the Patient with Refractory Amegakaryocytic Thrombocytopenia, 25 Months Follow up.A general process for the development of peptide-based immunoassays for monoclonal antibodies.Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphomaSuppression of human prostate tumor growth by a unique prostate-specific monoclonal antibody F77 targeting a glycolipid markerIncidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections.
P2860
Q22010908-8EBA2CC7-2BFF-41A1-9EA7-081175F17A84Q24535231-1C06CEB4-A3E8-4DBA-AE52-E2EA2DA553C9Q24605057-7B336346-BA81-4B29-8C1C-496E16370023Q24607358-BF47788A-4197-45CD-82A9-C097C73D1A9EQ24617708-E3ADAA05-49F6-46A0-AC41-0FF591A10259Q24644883-D6D1FE10-2D35-4EA2-A036-96172BD160CAQ24804504-913F64DF-062F-4EBA-A7FD-81850A8B3C2EQ24815753-8B148253-8D01-4E33-8F3E-A8B60EDE8E52Q26775602-0161C56F-4CD2-4419-B6EB-E9A2D3A384AFQ26777394-19E43BBE-32CF-497E-B392-0870B95C8ADCQ26783195-047A2829-B154-49E2-8B91-511D7981D2B6Q26784480-2C282E5F-B676-4F28-8C21-1E957459FB3AQ26785963-ACA8E29E-54E2-4897-8FDD-1D2B2785DA36Q26830484-1F305FE3-60BB-46CB-86C8-A311D8A48699Q27004436-72E770C7-78B2-49FD-B8CC-10F21F2DFA48Q27004638-6F4CF6C7-9F02-42D9-A41A-E140B819A297Q27006179-B70371E9-E5C1-42FA-A7E7-3B3CB73F7C11Q27021939-B5F5E37E-9650-4B36-967F-47693067EF55Q28077270-77A88485-0AFF-4F42-BC44-1D952F5486EFQ28083907-47E38D08-4C2B-498E-A0F2-DF266D5EA744Q28084276-5C40C583-47DE-4521-B0D0-B1E0603CDAC1Q28087820-2664D533-80DE-48F8-9EE6-9A385FDAC1E0Q28088598-86513DEF-EC5C-4188-BBB1-9A19E9CAC3EDQ30278460-D5E84532-01BB-4AA4-BF0F-92BC4BA5CAB7Q30363975-78763BCC-A1CF-4A55-9B64-E1166EB52815Q30395200-D2E49A6C-67EF-497B-B6B6-4B7FE65204A3Q30419228-DD824F5E-FEAE-4743-9AC7-4AFDE0521AFCQ30421637-0EF88806-63A5-4178-AA7C-3479132D2425Q30436996-D282C628-086A-4919-8CB4-72E82555C7BDQ30764873-7B7A651D-4798-44E3-8793-E3F785F96321Q30847784-CAC76052-043B-4511-B253-CCAD00FC1CFDQ33325581-E86F36A1-E641-47FA-8538-341A0496EC03Q33369574-BFAB931B-7B9E-4E5C-AEAA-9426D017112AQ33377109-F0496FB1-BB19-4F1C-B4DB-767E5CF3A055Q33405150-CAAF52FF-CC72-453D-89C3-58D6FF6E1DF5Q33415094-9C00512D-7DBD-4DD4-8C3D-957C2872271AQ33525284-41D57EC1-8A12-461C-81F0-F88FCBD07DE7Q33599174-0DC3EEBA-6FC4-4362-8836-9BE4ADBC693FQ33640235-89FE08DF-A5A0-4D5F-8280-F86BC712C6F7Q33668990-60EBD7F2-EAEC-46AC-B5E5-D04961ABF6A7
P2860
IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.
description
1997 nĆ® lÅ«n-bĆ»n
@nan
1997 Õ©ÕøÖÕ”ÕÆÕ”Õ¶Õ« ÕÕ„ÕŗÕæÕ„Õ“Õ¢Õ„ÖÕ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕøÖÕ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ ÕµÖ
Õ¤ÕøÖÕ”Õ®
@hyw
1997 Õ©Õ¾Õ”ÕÆÕ”Õ¶Õ« Õ½Õ„ÕŗÕæÕ„Õ“Õ¢Õ„ÖÕ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕ¾Õ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ Õ°ÕøÕ¤Õ¾Õ”Õ®
@hy
1997幓ć®č«ę
@ja
1997幓č«ę
@yue
1997幓č«ę
@zh-hant
1997幓č«ę
@zh-hk
1997幓č«ę
@zh-mo
1997幓č«ę
@zh-tw
1997幓č®ŗę
@wuu
name
IDEC-C2B8 (Rituximab) anti-CD2 ...... -grade non-Hodgkin's lymphoma.
@ast
IDEC-C2B8 (Rituximab) anti-CD2 ...... -grade non-Hodgkin's lymphoma.
@en
IDEC-C2B8
@nl
type
label
IDEC-C2B8 (Rituximab) anti-CD2 ...... -grade non-Hodgkin's lymphoma.
@ast
IDEC-C2B8 (Rituximab) anti-CD2 ...... -grade non-Hodgkin's lymphoma.
@en
IDEC-C2B8
@nl
prefLabel
IDEC-C2B8 (Rituximab) anti-CD2 ...... -grade non-Hodgkin's lymphoma.
@ast
IDEC-C2B8 (Rituximab) anti-CD2 ...... -grade non-Hodgkin's lymphoma.
@en
IDEC-C2B8
@nl
P2093
P1433
P1476
IDEC-C2B8 (Rituximab) anti-CD2 ...... -grade non-Hodgkin's lymphoma.
@en
P2093
Dallaire BK
Grillo-LĆ³pez AJ
Janakiraman N
Maloney DG
Neidhart JA
P304
P407
P577
1997-09-01T00:00:00Z